Literature DB >> 30089726

Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.

Mahmoud H Abou Alaiwa1, Jan L Launspach1, Brenda Grogan2, Suzanne Carter2, Joseph Zabner1, David A Stoltz1,3, Pradeep K Singh4, Edward F McKone2, Michael J Welsh1,3,5.   

Abstract

BACKGROUND: Disruption of cystic fibrosis transmembrane conductance regulator (CFTR) anion channel function causes cystic fibrosis (CF), and lung disease produces most of the mortality. Loss of CFTR-mediated HCO3- secretion reduces the pH of airway surface liquid (ASL) in vitro and in neonatal humans and pigs in vivo. However, we previously found that, in older children and adults, ASL pH does not differ between CF and non-CF. Here, we tested whether the pH of CF ASL increases with time after birth. Finding that it did suggested that adaptations by CF airways increase ASL pH. This conjecture predicted that increasing CFTR activity in CF airways would further increase ASL pH and also that increasing CFTR activity would correlate with increases in ASL pH.
METHODS: To test for longitudinal changes, we measured ASL pH in newborns and then at 3-month intervals. We also studied people with CF (bearing G551D or R117H mutations), in whom we could acutely stimulate CFTR activity with ivacaftor. To gauge changes in CFTR activity, we measured changes in sweat Cl- concentration immediately before and 48 hours after starting ivacaftor.
RESULTS: Compared with that in the newborn period, ASL pH increased by 6 months of age. In people with CF bearing G551D or R117H mutations, ivacaftor did not change the average ASL pH; however reductions in sweat Cl- concentration correlated with elevations of ASL pH. Reductions in sweat Cl- concentration also correlated with improvements in pulmonary function.
CONCLUSIONS: Our results suggest that CFTR-independent mechanisms increase ASL pH in people with CF. We speculate that CF airway disease, which begins soon after birth, is responsible for the adaptation. FUNDING: Vertex Inc., the NIH (P30DK089507, 1K08HL135433, HL091842, HL136813, K24HL102246), the Cystic Fibrosis Foundation (SINGH17A0 and SINGH15R0), and the Burroughs Wellcome Fund.

Entities:  

Keywords:  Epithelial transport of ions and water; Ion channels; Pulmonology

Mesh:

Substances:

Year:  2018        PMID: 30089726      PMCID: PMC6129116          DOI: 10.1172/jci.insight.121468

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  44 in total

1.  Medical reversal of chronic sinusitis in a cystic fibrosis patient with ivacaftor.

Authors:  Eugene H Chang; Xiao Xiao Tang; Viral S Shah; Janice L Launspach; Sarah E Ernst; Brieanna Hilkin; Philip H Karp; Mahmoud H Abou Alaiwa; Scott M Graham; Douglas B Hornick; Michael J Welsh; David A Stoltz; Joseph Zabner
Journal:  Int Forum Allergy Rhinol       Date:  2014-10-31       Impact factor: 3.858

2.  Ivacaftor-Induced Proteomic Changes Suggest Monocyte Defects May Contribute to the Pathogenesis of Cystic Fibrosis.

Authors:  Katherine B Hisert; Kelly Q Schoenfelt; Gordon Cooke; Brenda Grogan; Jan L Launspach; Charles G Gallagher; Seamas C Donnelly; Michael J Welsh; Pradeep K Singh; Edward F McKone; Lev Becker
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

Review 3.  Cystic fibrosis genetics: from molecular understanding to clinical application.

Authors:  Garry R Cutting
Journal:  Nat Rev Genet       Date:  2014-11-18       Impact factor: 53.242

4.  Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.

Authors:  Katherine B Hisert; Sonya L Heltshe; Christopher Pope; Peter Jorth; Xia Wu; Rachael M Edwards; Matthew Radey; Frank J Accurso; Daniel J Wolter; Gordon Cooke; Ryan J Adam; Suzanne Carter; Brenda Grogan; Janice L Launspach; Seamas C Donnelly; Charles G Gallagher; James E Bruce; David A Stoltz; Michael J Welsh; Lucas R Hoffman; Edward F McKone; Pradeep K Singh
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

5.  Breath condensate pH in children with cystic fibrosis and asthma: a new noninvasive marker of airway inflammation?

Authors:  Giovanna E Carpagnano; Peter J Barnes; Jackie Francis; Nicola Wilson; Andrew Bush; Sergei A Kharitonov
Journal:  Chest       Date:  2004-06       Impact factor: 9.410

6.  Optical imaging of Ca2+-evoked fluid secretion by murine nasal submucosal gland serous acinar cells.

Authors:  Robert J Lee; Maria P Limberis; Michael F Hennessy; James M Wilson; J Kevin Foskett
Journal:  J Physiol       Date:  2007-05-24       Impact factor: 5.182

7.  Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth.

Authors:  David A Stoltz; David K Meyerholz; Alejandro A Pezzulo; Shyam Ramachandran; Mark P Rogan; Greg J Davis; Robert A Hanfland; Chris Wohlford-Lenane; Cassie L Dohrn; Jennifer A Bartlett; George A Nelson; Eugene H Chang; Peter J Taft; Paula S Ludwig; Mira Estin; Emma E Hornick; Janice L Launspach; Melissa Samuel; Tatiana Rokhlina; Philip H Karp; Lynda S Ostedgaard; Aliye Uc; Timothy D Starner; Alexander R Horswill; Kim A Brogden; Randall S Prather; Sandra S Richter; Joel Shilyansky; Paul B McCray; Joseph Zabner; Michael J Welsh
Journal:  Sci Transl Med       Date:  2010-04-28       Impact factor: 17.956

Review 8.  Origins of cystic fibrosis lung disease.

Authors:  David A Stoltz; David K Meyerholz; Michael J Welsh
Journal:  N Engl J Med       Date:  2015-01-22       Impact factor: 91.245

9.  Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation.

Authors:  Daniel Gelfond; Sonya Heltshe; Changxing Ma; Steven M Rowe; Carla Frederick; Ahmet Uluer; Leonard Sicilian; Michael Konstan; Elizabeth Tullis; R N Christine Roach; Katherine Griffin; Elizabeth Joseloff; Drucy Borowitz
Journal:  Clin Transl Gastroenterol       Date:  2017-03-16       Impact factor: 4.488

10.  Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung.

Authors:  Alejandro A Pezzulo; Xiao Xiao Tang; Mark J Hoegger; Mahmoud H Abou Alaiwa; Shyam Ramachandran; Thomas O Moninger; Phillip H Karp; Christine L Wohlford-Lenane; Henk P Haagsman; Martin van Eijk; Botond Bánfi; Alexander R Horswill; David A Stoltz; Paul B McCray; Michael J Welsh; Joseph Zabner
Journal:  Nature       Date:  2012-07-04       Impact factor: 49.962

View more
  8 in total

Review 1.  Building global development strategies for cf therapeutics during a transitional cftr modulator era.

Authors:  N Mayer-Hamblett; S van Koningsbruggen-Rietschel; D P Nichols; D R VanDevanter; J C Davies; T Lee; A G Durmowicz; F Ratjen; M W Konstan; K Pearson; S C Bell; J P Clancy; J L Taylor-Cousar; K De Boeck; S H Donaldson; D G Downey; P A Flume; P Drevinek; C H Goss; I Fajac; A S Magaret; B S Quon; S M Singleton; J M VanDalfsen; G Z Retsch-Bogart
Journal:  J Cyst Fibros       Date:  2020-06-07       Impact factor: 5.482

2.  Vaporized E-Cigarette Liquids Induce Ion Transport Dysfunction in Airway Epithelia.

Authors:  Vivian Y Lin; Matthew D Fain; Patricia L Jackson; Taylor F Berryhill; Landon S Wilson; Marina Mazur; Stephen J Barnes; J Edwin Blalock; S Vamsee Raju; Steven M Rowe
Journal:  Am J Respir Cell Mol Biol       Date:  2019-08       Impact factor: 6.914

3.  Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells.

Authors:  Vinciane Saint-Criq; Iram J Haq; Aaron I Gardner; James P Garnett; Christopher Ward; Malcolm Brodlie; Michael A Gray
Journal:  J Vis Exp       Date:  2019-06-13       Impact factor: 1.424

4.  Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.

Authors:  Edward F McKone; Pradeep K Singh; Samantha L Durfey; Sudhakar Pipavath; Anna Li; Anh T Vo; Anina Ratjen; Suzanne Carter; Sarah J Morgan; Matthew C Radey; Brenda Grogan; Stephen J Salipante; Michael J Welsh; David A Stoltz; Christopher H Goss
Journal:  mBio       Date:  2021-12-14       Impact factor: 7.867

5.  Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.

Authors:  David P Nichols; Alex C Paynter; Sonya L Heltshe; Scott H Donaldson; Carla A Frederick; Steven D Freedman; Daniel Gelfond; Lucas R Hoffman; Andrea Kelly; Michael R Narkewicz; Jessica E Pittman; Felix Ratjen; Margaret Rosenfeld; Scott D Sagel; Sarah Jane Schwarzenberg; Pradeep K Singh; George M Solomon; Michael S Stalvey; John P Clancy; Shannon Kirby; Jill M Van Dalfsen; Margaret H Kloster; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2022-03-01       Impact factor: 30.528

6.  Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators.

Authors:  Tayyab Rehman; Philip H Karp; Ping Tan; Brian J Goodell; Alejandro A Pezzulo; Andrew L Thurman; Ian M Thornell; Samantha L Durfey; Michael E Duffey; David A Stoltz; Edward F McKone; Pradeep K Singh; Michael J Welsh
Journal:  J Clin Invest       Date:  2021-08-16       Impact factor: 19.456

Review 7.  Airway Surface Liquid pH Regulation in Airway Epithelium Current Understandings and Gaps in Knowledge.

Authors:  Miroslaw Zajac; Elise Dreano; Aurelie Edwards; Gabrielle Planelles; Isabelle Sermet-Gaudelus
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

8.  Paracellular bicarbonate flux across human cystic fibrosis airway epithelia tempers changes in airway surface liquid pH.

Authors:  Ian M Thornell; Tayyab Rehman; Alejandro A Pezzulo; Michael J Welsh
Journal:  J Physiol       Date:  2020-07-24       Impact factor: 6.228

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.